Emerging Modalities Stand Out In Recovering Korean Deal Market

ADCs, TPDs Gain Prominence

While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.

dealmaking — LigaChem, Orum Lead ADC Deals, While SK Biopharm Moves Into TPD, RPT • Source: Shutterstock

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as other road blocks, it is crucial for companies to adopt more efficient and effective strategies along with the government’s strong support.

A new policy report from the Korea Pharmaceutical and Bio-Pharma Manufacturers’ Association (KPBMA) notes that licensing activities and mergers and...